Company News: Page (1) of 1 - 04/17/12 Email this story to a friend. email article Print this page (Article printing at page facebook

Implant Sciences Adds Printing Capability to QS-H150 Explosives Trace Detector

(April 17, 2012)

WILMINGTON, MA -- (Marketwire) -- 04/17/12 -- Implant Sciences Corporation (OTCQB: IMSC) (PINKSHEETS: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced a key product enhancement for its Quantum Sniffer™ QS-H150 handheld explosives trace detectors. Using the QS-H150 Printing Kit, users will be able to print detection results, creating a permanent record of the explosives screening activity.

Available for purchase now, the kit includes a small, portable, thermal printer, an interface cable, and paper. The system can be configured in either automatic or manual printing modes. Each printout provides complete sample information including date and time, substances detected, system performance parameters, and more.

"The ability to print detection results increases the usefulness of the QS-H150 in several market segments, including checkpoint screening and air cargo," stated Implant Sciences President and CEO Glenn D. Bolduc. "Implant Sciences' commitment to satisfying customer needs has helped make our products the choice of security professionals around the world."

About the Quantum Sniffer™ QS-H150
The QS-H150 is a handheld explosives trace detector that uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. The QS-H150 uses no radioactive materials and features a low-maintenance design that is self-calibrating and self-clearing, providing very high levels of operational availability.

About Implant Sciences

Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive and narcotics trace detection systems which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and the Company's QS-B220 bench-top explosives and narcotics trace detector has received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; that our success depends on our ability to obtain new patents and operate without infringing on the proprietary rights of others; that we may not obtain the patents we have applied for; that the validity and breadth of claims in technology patents involve complex legal and factual questions and, therefore, may be highly uncertain; that any patents we may obtain may be may be challenged and subsequently invalidated, that we may incur substantial costs in asserting our patent rights; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Add to Digg Bookmark with Add to Newsvine

Implant Sciences Corporation
Company Contact:
Glenn Bolduc
Email Contact


Investor Contact:
Laurel Moody
Email Contact

Copyright @ Marketwire

Page: 1

Related Keywords: Implant Sciences Corporation, USA, Marketwire, , Business, Other,

Content-type: text/html  Rss  Add to Google Reader or
Homepage    Add to My AOL  Add to Excite MIX  Subscribe in
NewsGator Online 
Real-Time - what users are saying - Right Now!

Our Privacy Policy --- @ Copyright, 2015 Digital Media Online, All Rights Reserved